Rebecca Li has over 17 years of experience spanning the entire drug development process with experience in Biotech, Pharma and CRO environments. Dr. Li currently serves as the Executive Director of the MRCT Center at Harvard. The Center was chartered to improve the design, conduct and oversight of multi-regional clinical trials in the developing world and simplifying research through best practices. Prior to joining the MRCT Center, Dr. Li was at the New England Research Institutes for 6 years serving as the Vice President of Clinical Research with oversight of clinical trials (Phase I, II and III) and registries as well as Business Development. She also was employed at Wyeth Research (currently Pfizer) and served as the Associate Director in Translational Clinical Research. In this role, she designed protocols and had responsibility for implementing exploratory clinical biomarkers into trial design and coordinating pharmacogenomics efforts cross-functionally within the company, CROs and the clinical sites. Also at Wyeth, she worked at the bench and with animal models within the Discovery Research and Product Development departments and brought a recombinant human protein therapeutic from bench to clinic. She started her career at a biotechnology company, CytoTherapeutics, focused on development of an implantable cell-based therapeutic. She graduated with her PhD from Johns Hopkins University, Department of Biomolecular and Chemical Engineering and held an adjunct Associate Professor position at Brown University in the department of Pharmacology, Physiology and Biotechnology from 1994-2006. She has authored numerous peer-reviewed journal articles and book chapters.